Bilimsel çalışmalar

Uzm. Dr. Gözde Ağdaş

27 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16868-5 Açık erişimli tam metinKaynak: OpenAlex

  2. Meme Kanseri

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852 Açık erişimli tam metinKaynak: OpenAlex

  3. Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020642 PMID 41598581 Açık erişimli tam metinKaynak: ORCID

  4. Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

    Scientific reports, 2026

    DOI 10.1038/s41598-026-50526-x PMID 42103792 Açık erişimli tam metinKaynak: Europe PMC

  5. The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

    Discover oncology, 2026

    DOI 10.1007/s12672-026-04705-x PMID 41721952 Açık erişimli tam metinKaynak: Europe PMC

  6. Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

    Scientific reports, 2026

    DOI 10.1038/s41598-026-48955-9 PMID 41981174 Açık erişimli tam metinKaynak: Europe PMC

  7. Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancer

    Expert review of anticancer therapy, 2026

    DOI 10.1080/14737140.2026.2615853 PMID 41511755 2 atıf (Europe PMC) Kaynak: ORCID

  8. Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab

    Discover Oncology, 2026

    DOI 10.1007/s12672-026-04859-8 PMID 42014558 Açık erişimli tam metinKaynak: OpenAlex

  9. Integrating molecular and clinical determinants of survival in a real-world glioblastoma cohort

    Journal of Medicine and Palliative Care, 2026

    DOI 10.47582/jompac.1850445 Açık erişimli tam metinKaynak: ORCID

  10. IMMUNE-RELATED ADVERSE EVENTS AND THEIR MANAGEMENT IN CANCER PATIENTS AGED 75 YEARS AND OLDER RECEIVING IMMUNOTHERAPY

    Acta Medica Nicomedia, 2026

    DOI 10.53446/actamednicomedia.1906747 Açık erişimli tam metinKaynak: ORCID

  11. Real-world outcomes of first-line THP in de-novo HER2-positive metastatic breast cancer: a retrospective analysis of prognostic factors Including hormone receptor status, performance status, and metastatic pattern

    Journal of Health Sciences and Medicine, 2026

    DOI 10.32322/jhsm.1943147 Açık erişimli tam metinKaynak: ORCID

  12. Comparison of perioperative chemotherapy and neoadjuvant chemoradiotherapy (CRT) in locally advanced resectable distal esophageal/esophagogastric junction (EGJ) adenocarcinomas

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16110-2 PMID 42151898 Açık erişimli tam metinKaynak: ORCID

  13. Evaluation of the frequency of Helicobacter pylori infection and atrophic gastritis in patients diagnosed with celiac disease

    Turkish Journal of Clinics and Laboratory, 2026

    DOI 10.18663/tjcl.1804461 Açık erişimli tam metinKaynak: ORCID

  14. The prognostic impact of anemia in recurrent esophageal squamous cell carcinoma

    Anatolian Current Medical Journal, 2026

    DOI 10.38053/acmj.1827779 Açık erişimli tam metinKaynak: ORCID

  15. Prognostic Impact of RAS Mutation and Biologic Therapy in Second-Line Treatment of De-Novo Metastatic Colorectal Cancer: A Real-World Retrospective Analysis

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.269385 Kaynak: ORCID

  16. Predicting the Effectiveness of 2 Chemotherapy Regimens Applied to Breast Cancer Patients by Nutritional and Inflammatory Status

    Medical science monitor : international medical journal of experimental and clinical research, 2026

    DOI 10.12659/msm.951548 PMID 41572592 Açık erişimli tam metinKaynak: Europe PMC

  17. Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status

    Medical science monitor : international medical journal of experimental and clinical research, 2026

    DOI 10.12659/msm.951829 PMID 41508562 Açık erişimli tam metinKaynak: Europe PMC

  18. Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study

    Frontiers in Immunology, 2026

    DOI 10.3389/fimmu.2026.1714533 PMID 41766853 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  19. Hormon Reseptörü Pozitif ve HER2 Negatif Meme Kanserinde Neoadjuvan Tedavi

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852.c2768 Kaynak: OpenAlex

  20. Prognostic evaluation of dirty necrosis and tumor necrosis in gastric cancers

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-39605-1 PMID 41673085 Açık erişimli tam metinKaynak: OpenAlex

  21. Efficacy of Subsequent Therapy in Patients with Hormone-Positive Advanced Breast Cancer with Disease Progression After CDK4/6 Inhibitor Therapy: Multicenter Real-Life Data

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14207376 PMID 41156245 Açık erişimli tam metinKaynak: ORCID

  22. The prognostic utility of the ESGO risk classification in endometrial carcinoma: a single-center retrospective cohort study

    Journal of Medicine and Palliative Care, 2025

    DOI 10.47582/jompac.1822658 Açık erişimli tam metinKaynak: ORCID

  23. Can Symptom Clusters Predict Stage, Resectability, and Survival in Pancreatic Cancer?

    Cancer Management and Research, 2025

    DOI 10.2147/cmar.s561301 PMID 41356429 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  24. Prognostic Significance of High-Risk versus Very High-Risk Classification in Non-Surgically Managed Prostate Cancer: A Retrospective Cohort Study

    Cancer Management and Research, 2025

    DOI 10.2147/cmar.s570916 PMID 41480518 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  25. A Novel Non-Invasive Biomarker for Gastric Cancer: Monocyte-to-HDL Ratio and Clinicopathological Parameters in Predicting Survival Outcomes

    Cancers, 2025

    DOI 10.3390/cancers17172816 PMID 40940914 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  26. Çölyak hastalığı tanılı hastalarda Helicobacter pylori enfeksiyonu ve atrofik gastrit sıklığının değerlendirilmesi

    DergiPark (Istanbul University), 2025

    Kaynak: OpenAlex

  27. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

    The Oncologist, 2023

    DOI 10.1093/oncolo/oyad257 PMID 37676712 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex